Valo Health

Boston, Massachusetts, United States All United States companies → — Founded 2019

AI Research Lab Biotech / Drug Discovery

Laboratory Medicine Oncology Pathology

Drug Discovery & Research

Series C

Website Claim this company

Products

Opal Computational

Valo Health

Drug Discovery & Research

Valo combines real-world data, AI, advanced causal inference techniques and predictive chemistry into a powerful drug discovery and development engine. Their approach involves AI-enabled human causal biology and closed-loop chemistry to find patterns in large-scale human data, identify novel disease targets, and rapidly engineer novel small molecules.

See all 1 product →

About Valo Health

Valo Health is a biotechnology company that leverages artificial intelligence (AI) and large-scale human-centric data to revolutionize drug discovery and development. The company’s core offering is the Opal Computational Platform™, an integrated system that combines machine learning, cloud computing, tissue biology, and patient data. This platform is designed to accelerate the identification of novel disease targets, engineer new small molecules, predict patient benefit, and optimize clinical trial design and execution.

Valo Health’s approach aims to address the inefficiencies of traditional drug development by creating a closed-loop system that integrates computational and empirical methods. By analyzing vast datasets, including clinical records, genomic information, proteomes, metabolomes, microbiomes, and radiographic images, Valo seeks to uncover causal relationships between genetic markers and diseases. This data-driven strategy is intended to lead to more impactful drug targets and therapeutics, developed faster and with greater precision, ultimately reducing costs, time, and failure rates in bringing life-changing treatments to patients.

The company’s initial therapeutic focus areas include cardiovascular diseases, neurodegeneration, and oncology, as well as metabolic and renal diseases. Valo Health aims to develop its own proprietary drug candidates internally, utilizing its Opal platform as the primary discovery tool, and also engages in strategic partnerships with other pharmaceutical companies.

Focus Areas

drug discovery drug development artificial intelligence machine learning human-centric data cardiovascular diseases neurodegeneration oncology cardiometabolic diseases

Business Intelligence

Technology

Opal Computational Platform, AI-enabled human causal biology, closed-loop chemistry, cloud-native

What Physicians Need to Know

AI-Powered Drug Discovery & Development

Valo Health leverages artificial intelligence (AI) and machine learning (ML) to transform the entire drug discovery and development process, aiming to reduce costs, time, and failure rates.

Human-Centric Data Approach

Valo utilizes a vast data lake comprising over 20 million de-identified patient records, some spanning 20-30 years, along with biobank samples, genomic, proteomic, metabolomic, microbiomic data, and medical imaging. This human-centric data is crucial for understanding disease causality, identifying patient subtypes, and pinpointing novel therapeutic targets.

Opal Computational Platform

Their proprietary Opal Computational Platform is an end-to-end, integrated system that combines machine learning, cloud computing, and human data to generate actionable insights across the drug development lifecycle.

Closed-Loop Chemistry Platform

Valo employs a closed-loop chemistry platform that enables the rapid development and optimization of small molecules from trillions of starting points, designed for predictable safety and efficacy in humans.

Focus Therapeutic Areas

Valo's initial and ongoing focus areas include cardiovascular diseases, neurodegeneration (e.g., Parkinson's disease), oncology, and cardiometabolic diseases (e.g., obesity, type 2 diabetes).

3D Engineered Human Tissue Models (Biowire)

They validate targets using proprietary 3D engineered human tissue models, such as the Biowire platform for cardiac tissues, which mimic mature human physiology and structure, offering a physiologically relevant response for drug discovery and predicting clinical efficacy.

Physician Tip

For physicians, Valo Health's approach means a potential for faster development of more effective and safer drugs, particularly in challenging areas like neurodegeneration, oncology, and cardiometabolic diseases. Their use of extensive human-centric data and AI aims to identify novel drug targets grounded in human evidence, predict patient response, and design more efficient clinical trials. This could lead to therapies that are better tailored to specific patient subtypes and have a higher probability of success in clinical settings, ultimately offering new and improved treatment options.

Valo Health's Opal Computational Platform is designed as an end-to-end workflow. They also engage in strategic partnerships, such as collaborations with Merck KGaA for neurodegenerative disorders and Novo Nordisk for cardiometabolic diseases, and Charles River Laboratories for AI-powered drug discovery (Logicau00ae). Their technology stack includes Cloudflare, Cloudflare DNS, and Microsoft 365, along with various programming languages (Python, R, Java, JavaScript, SQL, TypeScript, Matlab), databases (Cassandra, MySQL, Neo4j, Oracle, Snowflake, SQLite), and frameworks (Docker, Express, Flask, Jupyter, Kubernetes, React, Redux, Scikit, Spring, Terraform, Vue.js, Vuex). They also partner with nference for real-time access to a wide range of data modes, including insights from physicians' notes, medical imaging, and outcomes data.

At a glance

Founded 2019

HQ Boston, Massachusetts, United States · United States

CEO Brian M. Alexander

Funding Series C

Products 1

Visit site

Products by Valo Health

1 product in the directory

Opal Computational

Valo Health

Drug Discovery & Research

What the Web Says

Valo Health is a technology company focused on transforming drug discovery and development using AI and human-centric data. They aim to accelerate the creation of life-changing drugs while reducing costs, time, and failure rates. While the company is praised for its innovative technology and mission, employee morale has been impacted by layoffs and restructuring.

Overall: Mixed

Strengths

Incredible and disruptive technology for drug discovery and development.
Great pay and benefits.
Supportive and inclusive work environment with great colleagues.
Strong emphasis on work-life balance.
Offers company equity and performance bonuses.
Dedicated diversity and inclusion staff and initiatives.

Limitations

Layoffs and restructuring have diminished employee morale.
Poor prospects for career advancement; official guidelines not always followed.
Management issues and lack of accountability in some areas.
Limited resources and changing priorities can be stressful.
Job security concerns.
Some reviews for a product named 'Valo' (not explicitly 'Valo Health') on G2 and Capterra are for different software products (e.g., AI coding assistants, collaboration tools, EHR systems, red light therapy devices), making it difficult to find specific product reviews for Valo Health's drug discovery platform.

Based on reviews from: Indeed.com, BioHackingTested.com, G2.com, Valohealth.com, SimplyHired.com, BuiltIn.com, PitchBook.com, Reddit.com, Capterra.com, PR Newswire, BBB Scam Tracker

Last updated: 2026-08-25

Videos

News, demos, and interviews about Valo Health.

Loading videos...

Videos load interactively. If none appear, search YouTube for Valo Health →

View all on YouTube

Press & Coverage

Valo Health

Valo Health Completes Enrollment of OPL-0401 Phase 2 Study for the Treatment of Diabetic Retinopathy

Valo Health announced the completion of enrollment for its OPL-0401 Phase 2 study, investigating an oral ROCK1/2 inhibitor for non-proliferative diabetic retinopathy. This marks a significant step in their AI-driven drug discovery efforts.

2024-03

Valo Health

Valo Health Announces Changes to its Board of Directors and Leadership Team

Valo Health, a technology company utilizing AI and large-scale data for drug discovery, announced updates to its Board of Directors and leadership team. These changes aim to strengthen the company's strategic direction.

2024-01

Valo Health

Valo Health Awarded Grant from The Michael J. Fox Foundation to Advance Parkinson's Disease Research

Valo Health received a research grant from The Michael J. Fox Foundation to advance Parkinson's disease research, leveraging its expertise in human data and AI-enabled analytical tools. The grant is part of the Targets to Therapies Initiative.

2025-09

Drug Discovery News

Valo, Merck KGaA collaboration targets Parkinson's complexity with human data

Valo Health announced a partnership with Merck KGaA to discover and develop novel treatments for Parkinson's disease and related disorders, with potential payments exceeding $3 billion. This collaboration combines Merck KGaA's neurology expertise with Valo's AI-enabled platforms.

2026-08

GlobeNewswire

Valo Health and Novo Nordisk expand collaboration to discover and develop novel treatments for cardiometabolic diseases

Valo Health and Novo Nordisk expanded their collaboration to discover and develop up to 20 novel drug programs for obesity, type 2 diabetes, and cardiovascular disease. The expanded agreement includes near-term payments of up to $190 million and potential milestone payments of approximately $4.6 billion.

2025-01

MedCity News

Valo Health CEO: We Don't Want Investors To Drive the Science

Brian Alexander, CEO of Valo Health, discussed the company's approach to drug development, emphasizing the use of AI and human data to improve success probabilities rather than focusing solely on investor-driven clinical trials. Valo aims to partner with larger companies for commercialization.

2026-02

Business Wire

Valo Health and nference Announce Long-term Partnership to Accelerate Human-Centric Drug Discovery and Development

Valo Health and nference announced a multi-year collaboration to accelerate human-centric drug discovery and development by leveraging nference's comprehensive, de-identified patient-level data. This partnership will enhance Valo's Opal Computational Platform.

2025-03

Valo Health

Valo Health Announces Publication of the Journal of Clinical Investigation of a New Therapeutic Approach to Improve CD8+ T Cell Function

Valo Health announced the publication of a proof of concept for its preclinical asset, OPL-0101, in the Journal of Clinical Investigation Insight. The study demonstrates a novel therapeutic approach to improve CD8+ T cell function.

2022-06

Frequently Asked Questions

How does Valo Health leverage AI and machine learning to accelerate drug discovery and development, particularly in areas like cardiovascular diseases, neurodegeneration, and oncology?

Valo Health utilizes a proprietary AI-powered computational platform, Opal, to integrate and analyze vast amounts of human-centric data, including genomics, electronic health records, and real-world data. This platform helps identify novel drug targets, predict drug efficacy and safety, and optimize lead compounds across various therapeutic areas, aiming to accelerate the drug discovery and development process.

What specific products or therapeutic candidates does Valo Health currently have in its pipeline, especially concerning cardiometabolic diseases, neurodegeneration, and oncology?

Valo Health has a pipeline of therapeutic candidates across several disease areas, including cardiovascular, cardiometabolic, neurodegeneration, and oncology. While specific product names and detailed clinical trial phases would require direct inquiry or review of their latest public reports, their focus is on developing novel small molecules and biologics driven by their AI-powered platform.

How does Valo Health ensure the compliance and ethical use of human-centric data within its AI models for drug discovery and development?

Valo Health prioritizes data privacy and ethical compliance by adhering to relevant regulations like HIPAA and GDPR. They employ robust data governance frameworks, de-identification techniques, and secure data environments to ensure the responsible and ethical use of human-centric data in their AI models, maintaining patient confidentiality and data integrity.

What is Valo Health's partnership model, and how can healthcare institutions or physician groups collaborate with them on research or development initiatives?

Valo Health engages in various partnership models, including collaborations with pharmaceutical companies, academic institutions, and healthcare organizations. These partnerships can range from co-development agreements and licensing deals to research collaborations aimed at leveraging their AI platform and data science expertise to address unmet medical needs. Specific collaboration opportunities would depend on mutual strategic alignment and scientific objectives.

What is the long-term stability and funding outlook for Valo Health, and how does this impact the reliability of potential future drug candidates or collaborations?

Valo Health has secured significant funding rounds from prominent investors, indicating strong financial backing and investor confidence in its AI-driven drug discovery model. This financial stability supports their long-term research and development initiatives, suggesting a reliable trajectory for advancing their pipeline and sustaining collaborations.